Predict your next investment

Non-Profit Foundation
alzdiscovery.org

See what CB Insights has to offer

Investments

17

Portfolio Exits

4

Funds

1

Partners & Customers

4

About Alzheimer's Drug Discovery Foundation

Alzheimer's Drug Discovery Foundation (ADDF) is a public charity that aims to accelerate the discovery and development of drugs to prevent, treat, and cure Alzheimer's disease, related dementias, and cognitive aging.

Alzheimer's Drug Discovery Foundation Headquarter Location

57 West 57th STreet Suite 904

New York, New York, 10019,

United States

212-901-8000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Alzheimer's Drug Discovery Foundation News

Alzheimers Drug Discovery Foundation and Foundation for Mitochondrial Medicine Partner to Support Novel Research for MitochondrialDirected Therapies

Feb 27, 2014

Frequency of mitochondrial mutations in non-syndromic hearing loss as well as possibly responsible variants found by whole mitochondrial genome screening The Alzheimer’s Drug Discovery Foundation (ADDF) and the Foundation for Mitochondrial Medicine (FMM) announced today that they have awarded $200,000 in funding to James Bennett, M.D., Ph.D. to further research gene therapy of mitochondrial protein in the brains of mice with experimental Alzheimer’s disease. Bennett is studying rhTFAM, a novel human mitochondrial protein shown to increase mitochondrial function in cell and animal models. The protein has shown to restore memory function of aged mice while increasing mitochondrial function in brains, suggesting it has great potential to do the same in humans with impaired cognition and early Alzheimer’s disease. rhTFAM was invented and is being developed commercially by Gencia Corporation, located in Charlottesville, Va. Bennett’s research will provide critical data to support the use of rhTFAM in the use of humans. Mitochondria dysfunction underlies many different diseases. The brain is particularly vulnerable to changes in energy use that occur with age or because of underlying disease pathology. Previous research has shown that mitochondrial in the brain are dysfunctional in early stage of Alzheimer’s, and these changes contribute to the later loss of mitochondrial function and the onset and progression of the disease. “Novel therapies that can correct defects in mitochondria functioning have the potential to impact many different diseases,” said Bennett. “Thanks to funding support from ADDF and FMM, I’m able to continue my research into one of these novel therapies and determine possible implications for its use in a variety of areas, from early childhood genetic diseases to late-life neurodegenerative diseases such as Alzheimer’s.” “We are delighted to support Dr. Bennett’s research involving the rhTFAM mitochondrial protein and the potential it has to impact the progression of Alzheimer’s disease,” said Diana Shineman, Ph.D., director of Scientific Affairs for ADDF. “The translational nature of Dr. Bennett’s research could have critical applications beyond Alzheimer’s disease to other related disorders that affect millions of Americans.” “We are pleased to partner with ADDF and ensure that Dr. Bennett’s innovative, translation research is conducted,” said Laura Stanley, executive director of FMM. “Our mission is to fund the most promising treatments for the many forms of mitochondrial disease. Research like Dr. Bennett’s can unlock potential cures for many related diseases, including Alzheimer’s disease, Autism, Parkinson’s disease and others.” Bennett holds the Bemiss Chair and is founding director of the Virginia Commonwealth University Parkinson's and Movement Disorders Center. Bennett has held several individual NIH grants and has led two multi-investigator NIH Programs. He oversaw projects and directed the NIH-funded University of Virginia Udall Parkinson's Research Center of Excellence for ten years. He has over 140 peer-reviewed publications that have encompassed Parkinson's pharmacology and mitochondrial mechanisms of neurodegeneration. He has held multiple Investigational New Drug (IND) applications and is the inventor of worldwide patents involving use of a novel neuroprotective drug. His current research involves the molecular biology and pharmacology of mitochondrial dysfunction in neurodegenerative diseases, such as Alzheimer's, Parkinson's and Lou Gehrig's diseases (amyotrophic lateral sclerosis). He graduated from the University of Florida in 1970 with a BS in Chemistry (with Honors). He attended Johns Hopkins University Medical School and received his M.D. degree in 1974 and Ph.D. in Pharmacology in 1977. About the Alzheimer’s Drug Discovery Foundation (ADDF): The mission of the ADDF is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s diseases, related dementias and cognitive aging. The ADDF has granted more than $65 million to fund nearly 450 Alzheimer’s drug discovery programs in academic centers and biotechnology companies in 18 countries. For more information, visit www.AlzDiscovery.org . About the Foundation for Mitochondrial Medicine (FMM): The Foundation for Mitochondrial Medicine’s mission is to support the development of the most promising research and treatments for the many forms of mitochondrial disease. Cures for mitochondrial diseases could impact cures for Autism, Alzheimer’s, Parkinson’s, and Lou Gehrig’s disease among others. For more information on FMM funded research such as functional MRI studies on cognitive fatigue and testing of new drug compounds, visit www.mitochondrialdiseases.org About VCU and the VCU Medical Center: Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 223 degree and certificate programs in the arts, sciences and humanities. Sixty-eight of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 13 schools and one college. MCV Hospitals and the health sciences schools of VCU comprise the VCU Medical Center, one of the nation’s leading academic medical centers. For more, see www.vcu.edu . Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140227005816/en/

Alzheimer's Drug Discovery Foundation Investments

17 Investments

Alzheimer's Drug Discovery Foundation has made 17 investments. Their latest investment was in Life Biosciences as part of their Grant on September 9, 2021.

CBI Logo

Alzheimer's Drug Discovery Foundation Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/28/2021

Grant

Life Biosciences

Yes

1

8/4/2021

Seed

C. Light Technologies

$0.5M

Yes

1

3/10/2021

Grant - II

Asceneuron

$2.2M

Yes

1

9/24/2020

Grant

Subscribe to see more

$99M

Subscribe to see more

10

9/22/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/28/2021

8/4/2021

3/10/2021

9/24/2020

9/22/2020

Round

Grant

Seed

Grant - II

Grant

Series A

Company

Life Biosciences

C. Light Technologies

Asceneuron

Subscribe to see more

Subscribe to see more

Amount

$0.5M

$2.2M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Alzheimer's Drug Discovery Foundation Portfolio Exits

4 Portfolio Exits

Alzheimer's Drug Discovery Foundation has 4 portfolio exits. Their latest portfolio exit was Amylyx Pharmaceuticals on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

1

9/18/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/26/2020

Acquired

Subscribe to see more

Subscribe to see more

10

12/15/2015

IPO

Subscribe to see more

Subscribe to see more

10

Date

1/7/2022

9/18/2020

5/26/2020

12/15/2015

Exit

IPO

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Alzheimer's Drug Discovery Foundation Fund History

1 Fund History

Alzheimer's Drug Discovery Foundation has 1 fund, including Diagnostics Accelerator.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/2/2019

Diagnostics Accelerator

$50M

2

Closing Date

4/2/2019

Fund

Diagnostics Accelerator

Fund Type

Status

Amount

$50M

Sources

2

Alzheimer's Drug Discovery Foundation Partners & Customers

4 Partners and customers

Alzheimer's Drug Discovery Foundation has 4 strategic partners and customers. Alzheimer's Drug Discovery Foundation recently partnered with Harrington Discovery Institute on July 7, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

7/20/2020

Partner

Harrington Discovery Institute

United States

1

4/3/2019

Partner

Amylyx Pharmaceuticals, Alzheimer's Association, and Cure Alzheimer's Fund

United States

Subscribe to see more

Subscribe to see more

10

1/12/2016

Partner

PsychoGenics

United States

Subscribe to see more

Subscribe to see more

10

10/24/2013

Partner

Harrington Discovery Institute

United States

Subscribe to see more

Subscribe to see more

10

Date

7/20/2020

4/3/2019

1/12/2016

10/24/2013

Type

Partner

Partner

Partner

Partner

Business Partner

Harrington Discovery Institute

Amylyx Pharmaceuticals, Alzheimer's Association, and Cure Alzheimer's Fund

PsychoGenics

Harrington Discovery Institute

Country

United States

United States

United States

United States

News Snippet

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Alzheimer's Drug Discovery Foundation Team

1 Team Member

Alzheimer's Drug Discovery Foundation has 1 team member, including current Executive Vice President, Nancy Lynn.

Name

Work History

Title

Status

Nancy Lynn

Executive Vice President

Current

Name

Nancy Lynn

Work History

Title

Executive Vice President

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.